2.80
-0.08 (-2.78%)
| Previous Close | 2.88 |
| Open | 2.89 |
| Volume | 479,705 |
| Avg. Volume (3M) | 322,948 |
| Market Cap | 66,555,720 |
| Price / Earnings (Forward) | 2.16 |
| Price / Book | 2.90 |
| 52 Weeks Range | |
| Earnings Date | 13 Nov 2025 |
| Diluted EPS (TTM) | -1.96 |
| Current Ratio (MRQ) | 0.220 |
| Operating Cash Flow (TTM) | -10.45 M |
| Levered Free Cash Flow (TTM) | 3.23 M |
| Return on Assets (TTM) | -191.74% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | NRX Pharmaceuticals, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 2.38 |
|
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 15.88% |
| % Held by Institutions | 13.34% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| One Wealth Management Investment & Advisory Services, Llc | 30 Jun 2025 | 15,041 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 40.00 (HC Wainwright & Co., 1,328.57%) | Buy |
| Median | 37.00 (1,221.43%) | |
| Low | 34.00 (D. Boral Capital, 1,114.29%) | Buy |
| Average | 37.00 (1,221.43%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 2.84 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| D. Boral Capital | 08 Sep 2025 | 34.00 (1,114.29%) | Buy | 2.84 |
| 22 Aug 2025 | 34.00 (1,114.29%) | Buy | 2.64 | |
| HC Wainwright & Co. | 08 Sep 2025 | 40.00 (1,328.57%) | Buy | 2.84 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |